Manulife Financial Corporation (MFC)

Valuation on Manulife Financial Corporation (MFC) is stretched relative to sovereign debt yields, but short interest is too crowded to bet on immediate downside.

On our desk, the debate centers on whether MFC's current valuation over 2x book value fully prices in its growth story. While the Q2 2026 adjusted EPS of $1.09 crushed expectations by 38% and core ROE improved to 16.3%, some portfolio managers are advising caution. The stock has run hard, and with Canadian financials looking a bit overvalued broadly, we are telling clients to wait for a market pullback or accumulation on weakness before adding new capital, despite the firm's attractive positioning relative to domestic banks.

From a fundamental modeling perspective, analysts evaluating MFC need to separate legacy overhangs from the accelerating engines in Asia and Global Wealth and Asset Management (WAM), which posted a 21% APE sales increase in Q2. When analyzing their path toward their 18%+ core ROE target by 2027, focus heavily on capital management metrics: they returned CAD 5.3B to shareholders over the past 12 months and maintain a formidable 136% LICAT ratio with CAD 26B in excess capital. Keep a close eye on expense ratios staying sub-45% as a primary operational KPI.

Watching the macro risk profile, we note that while Manulife's third long-term care reinsurance deal with Munich Re covering CAD 3.2B in reserves significantly helps transfer biometric risk, lingering vulnerabilities remain. Specifically, losses in the ALDA portfolio and headline contagion risks from private credit issues are weighing on sentiment. Furthermore, pressures from elevated disability claims in Canadian group insurance—expected to normalize by late 2026—and new regulatory changes in China and Hong Kong create clear downside execution risks that the market might be underestimating.